

# Injectables that Lower Glucose



Class/Main Action	Name	Dose Range	Considerations
<b>GLP-1 Receptor Agonist (GLP-1 RA)</b> <b>“Incretin Mimetic”</b> <ul style="list-style-type: none"> <li>Increases insulin release with food</li> <li>Slows gastric emptying</li> <li>Promotes satiety</li> <li>Suppresses glucagon</li> </ul>	exenatide (Byetta)	5 and 10 mcg BID	<b>Side effects for all:</b> Nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med. Renally excreted.  <b>Black box warning:</b> Thyroid C-cell tumor warning for exenatide XR, liraglutide, dulaglutide, and semaglutide (avoid if family history of medullary thyroid tumor). * Victoza significantly reduces risk of CV death, heart attack, and stroke.  Lowers A1c 0.5 – 1.6% Weight loss of 1.6 to 6.0kg†
	exenatide XR (Bydureon)	2mg 1x a week Pen injector - Bydureon BCise	
	liraglutide (Victoza)*	0.6 and 1.8 mg daily	
	dulaglutide (Trulicity)	0.75 and 1.5 mg 1x a week pen injector	
	semaglutide (Ozempic)†	0.5 and 1.0 mg 1x a week pen injector	
	lixisenatide (Adlyxin)	(Only available in combo with glargine, iGlarLixi, see below)	
<b>Amylin Mimetic</b> <ul style="list-style-type: none"> <li>Slows gastric emptying</li> <li>Suppresses glucagon</li> <li>Promotes satiety</li> </ul>	pramlintide (Symlin)	Type 1: 15 - 60 mcg; Type 2: 60 - 120 mcg  immediately before major meals	For Type 1 or 2 on insulin.  <b>Black box warning:</b> severe hypoglycemic risk 3 hrs post injection. Prevent hypoglycemia, decrease insulin dose when starting pramlintide. Side effects: nausea, weight loss.  Lowers A1c 0.5 – 1%

The information listed here are general guidelines only; please consult prescribing information for details.

# Insulin/Injectable Combos

Download **FREE CDE® Coach App** for latest Pocketcard versions and update notifications | [DiabetesEd.Net](http://DiabetesEd.Net)



Name	Combines	Considerations
<b>IDegLira*</b> Xultophy 100/3.6	Insulin degludec (IDeg or Tresiba) Ultra long insulin + Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA)	<p><b>Xultophy 100/3.6 pre-filled pen</b> = 100 units IDeg / 3.6 mg liraglutide per mL                      Once daily injection – Dose range 10 to 50 = 10 – 50 units IDeg + 0.36 -1.8 mg liraglutide</p> <p><b>Recommended starting dose:</b></p> <ul style="list-style-type: none"> <li>• 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide)</li> </ul> Titrate dose up or down by 2 units every 3-4 days to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 21 days.
<b>iGlarLixi*</b> Soliqua 100/33	Insulin glargine (Lantus) Basal Insulin + Lixisenatide (Adlyxin) GLP-1 Receptor Agonist	<p><b>Soliqua 100/33 Solostar Pen</b> = 100 units glargine / 33 µg lixisenatide per mL                      Once daily injection an hour prior to first meal of day.                      Dose range 15 – 60 = 15-60 units glargine + 5 – 20µg lixisenatide</p> <p><b>Recommended starting dose:</b></p> <ul style="list-style-type: none"> <li>• 15 units for pts not controlled on 30 units basal insulin or GLP-1 RA</li> <li>• 30 units for pts not controlled on 30 -60 units basal insulin or GLP-1 RA</li> </ul> Titrate dose up or down by 2-4 units every week to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 14 days.

**\*Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.**